Bayer Schering Pharma looks forward to phase III contraception trials
5 May 2009 00:00 in Pharmaceutical Company Product News
Bayer Schering Pharma is looking forward to beginning and developing its phase III clinical trials of an innovative female contraception patch, it has stated.
Some 3,300 women will take part in one of two global investigations to evaluate how reliable the treatment is and the first filing of the product is expected in 2012.
The patch combines low-dose ethinylestradiol and gestodene and is intended to be applied once a week. This will amount to three per cycle ? or every 21 days ? and one week off.
Dr Phil Smits is the head of women's healthcare at the business and explained the contraception will be the smallest, lowest dosed and only translucent product of its kind available on the market.
"We are optimistic that these attributes will make it an attractive option for women seeking alternative routes of hormonal contraception," he said.
Last week, the Bayer group released its first quarter 2009 financial results.
Management board chairman Werner Wenning explained although consumer health was down due to inventory reductions and lower consumer spending, the firm's pharmaceutical division achieved "pleasing" growth.
Other news stories from 05/05/2009
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
